Inibio is a biopharmaceutical startup founded in 2017 that focuses on innovative drug development within the biopharma and pharmaceutical industries. In its latest funding round in February 2022, the company secured a KRW41.50B Series B investment with participation from a consortium of investors, including Kiwoom Securities, Ryukyung PSG, SBI Investment, NH Hedge Asset Management, and Kudos Ventures. This investment signifies confidence in Inibio's potential for significant growth and impact within the healthcare and pharmaceutical sectors.
Inibio
Founded 2017
Series B
Total: $54.00B
Biopharma, Pharmaceutical
General Information
Company Name
Inibio
Founded Year
2017
Industries
Biopharma, Pharmaceutical
Funding Stage
Series B
BounceWatch is an independent company data service, not affiliated with Inibio. To contact Inibio, visit inibio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About Inibio
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | KRW41.50B | 5 |
|
08 Feb 2022 |
| Venture Round | KRW12.50B | - |
|
01 May 2021 |
| Seed Round | Undisclosed | 1 |
|
01 Jan 2019 |
FAQ About Inibio
Inibio was founded in 2017.
Inibio operates in Biopharma and Pharmaceutical.
Inibio has completed 3 funding rounds, raising a total of $54.00B. The latest funding stage is Series B.
We're actively collecting intelligence on Inibio.
Source: BounceWatch company record for Inibio, https://bouncewatch.com/company/inibio, updated 12 September 2024. When citing, please name BounceWatch and link this page.
